- Genentech-Immunogen breast cancer drug prolongs survival in trial
A 991-patient trial found that Genentech and Immunogen's T-DM1, or trastuzumab emtansine, was more effective than lapatinib plus capecitabine in extending both progression-free and overall survival of patients with HER2-positive breast cancer who previously received trastuzumab and a taxane. More patients who received the combo treatment also experienced moderate to severe side effects than those treated with T-DM1. MedPage Today (free registration) (10/1), Xconomy/San Francisco (10/1)       | Bayer, Onyx Win Quick FDA Approval on Stivarga in mCRC | | Bayer HealthCare Pharmaceuticals wasted no time moving the oral multikinase inhibitor Stiverga (regorafenib) to market in metastatic colorectal cancer (mCRC) following FDA approval. Although the move came one month ahead of the drug's PDUFA date of Oct. 27, the company already had product in its distribution channel. Find out the details. |  |
- Evotec and Bayer collaborate on R&D for 3 endometriosis drugs
Bayer Pharma and Evotec agreed to develop three clinical-stage treatments for endometriosis as part of a five-year, multitarget deal. The partners will work together on early research and preclinical characterization of drug candidates. Bayer will be in charge of development and commercialization. Evotec will receive about $15.4 million upfront and as much as $746 million in milestone fees, plus sales royalties. Genetic Engineering & Biotechnology News (10/1) - Medistem, Superview partner to develop stem cell-modifying antibodies
Medistem and Superview Biotechnology will use stem cell lines to screen monoclonal antibodies that could be used in regenerative medicine. The goal of the partnership is to find monoclonal antibodies that regulate the activity of stem cells as an alternative to stem cell-based treatments. Targeting endogenous stem cells using monoclonal antibodies "not only provides methods of activating stem cells but also allows for the development of stem cell adjuvant therapies that could be used to resurrect stem cell candidates that failed in clinical trials," Medistem CEO Thomas Ichim said. Genetic Engineering & Biotechnology News (10/1) - AstraZeneca's Iressa slows esophageal cancer in study
In a study, AstraZeneca's epidermal growth factor receptor inhibitor Iressa, or gefitinib, slowed disease progression but didn't improve survival of patients with advance esophageal cancer. Researcher David Ferry said overall survival was approximately 3.5 months for those who received Iressa or placebo. However, patients who took Iressa saw numerically small improvement in progression-free survival, Ferry said. MedPage Today (free registration) (9/29) - Business group talks to employers about biologics cost
The Midwest Business Group on Health plans to carry out a series of programs including educational seminars to help employers prepare for the costs of biologics, which could account for about 40% of employer drug costs by 2017, according to this article. "We're not going to reduce the costs of biologics, so employers need a good understanding of how these diseases can impact productivity," said Cheryl Larson, the group's vice president. Workforce online (9/28)  | Accelerate molecular simulations for your drug discovery research, with Accelrys Discovery Studio ® 3.5!
Designed to address the modeling challenge's faced by research scientists, Discovery Studio 3.5 is Accelrys' latest, and most complete modeling and simulation solution for small molecules and macromolecules-based drug design. Register for our webinar and learn about Accelrys Discovery Studio. | |
| Company & Financial News |  |  | | | Global Developments | | | | - Researchers want Alzheimer's stem cell therapy ready by 2016
South Korean researchers are working on a stem cell treatment for Alzheimer's disease, with the goal of having it ready to launch by 2016. The researchers said they have already applied for regulatory approval of clinical trials. Trials on mice showed the therapy is effective, and it does not trigger cancers, researchers said. The Korea Times (Seoul) (9/27) | Food & Agriculture | | | | - Prop 37 favors organics, not transparency
 California's Proposition 37, which would require mandatory labeling of food products that contain any biotech ingredients, has no valid basis and is a "wolf in sheep's clothing" intended to boost sales of organic food, lawyer David TerMolen writes. Processed foods could not be labeled "natural" and, conversely, any certified organic product would be exempt from any biotech co-mingling labeling requirements, he writes. Food Processing (9/30) | Industrial & Environmental | | | | | News from BIO | | | | - BIOtechNOW
BIOtechNOW is the first in a number of new products from BIO intended to enhance our communications with the biotech community -- not only with our members, but with other stakeholders as well. This e-newsletter, combined with its website, serves as our flagship in that effort. BIOtechNOW will offer original content that emphasizes the business needs of the industry; highlight BIO's advocacy efforts; and provide a portal to all BIO activities and events. Most importantly, it will spotlight for those outside the industry the value of biotechnology. Sign up for the e-newsletter.
| SmartQuote | | | |  | Even if you're on the right track, you'll get run over if you just sit there."
--Will Rogers,
American performer, humorist and critic  |
| | This SmartBrief was created for jmabs1@gmail.com
| | | Read more at SmartBrief.com | | A powerful website for SmartBrief readers including: | | | | | | | | | | Recent BIO SmartBrief Issues: - Monday, October 01, 2012
- Friday, September 28, 2012
- Thursday, September 27, 2012
- Wednesday, September 26, 2012
- Tuesday, September 25, 2012
| | | Lead Editor: Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | | | | | | © 1999-2012 SmartBrief, Inc.® Legal Information |
|
No comments:
Post a Comment